| |
|
|
| |
Controlled Release Cardiovascular Therapeutics
Drugs, Indications, Markets and Prospects
|
Publication: August 2011
Product Code: CRCV811K
|
The prevalence and incidence of cardiovascular conditions in
developed economies continue to increase, creating
challenges and opportunities for cardiovascular drug
developers. While the vast majority of drugs for treating
cardiovascular conditions are oral immediate release
products, issues related to drug safety and patient
compliance have focused attention on formulations that can
improve drug safety profiles and reduce dosing frequency.
Important treatment segments for controlled release
cardiovascular drugs include angina, hypertension,
arrhythmias, cholesterol, and peripheral artery disease.
Important growth factors for controlled release
cardiovascular drugs include evolving patient demographics,
environmental and lifestyle causative factors, increased
public awareness of cardiovascular conditions and their
associated morbidities, and expanded patient access to
cardiovascular treatment services. |
|
Highlights |
· Analyzes and evaluates
cardiovascular drugs formulated for controlled release and assesses
the market potential for existing and potential
future products
· Analyzes product
technologies and product development factors
· Provides
detailed assessments of key cardiovascular market segments, market
demographics and business strategies
· Provides market data
and forecasts to 2015
· Profiles market sector
participant companies, their product development
activities and strategies
|
|
Summary of Contents |
Executive Summary
Cardiovascular
Therapeutics - Market Dynamics
The
Cardiovascular Drug Landscape
Unmet Needs in
Cardiovascular Clinical Treatment
Cardiovascular
Drug Demand Drivers
Demographic Shifts
Evolving Drug Formulation Technology
Managed Care
Initiatives
Growth in Self Administration
Modified Release Technologies and Product
Segments
Oral
Advanced Film Coating
Systems
Bead Systems
Bi-layer Tablets
Tri-layer Tablets
Microtablets
Transdermal
Cardiovascular Controlled Release Product
Analysis
Clonidine
Diltiazem
Isosorbide
dinitrate
Isradipine
Metoprolol
Nicardipine
Nifedipine
Nitroglycerin
Nisoldipine
Pentoxifylline
Propanolol
Virapamil
Cardiovascular Drug Commercialization Factors
Cardiovascular Segments for Controlled Release
Therapeutics
Angina
Cholesterol Management
Heart Rhythm
Atrial Fibrillation
Arrhythmias
Hypertension
Peripheral Artery Disease
Market Factors
Regulations and Approvals
Managed Care and Healthcare Economics
Alliances
and Private Labeling
Sector Participant
Company Profiles
|
|
|
|
|
